02/01/2021 | Press release | Archived content
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
February 1, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: | CNS Pharmaceuticals, Inc. | |
Registration Statement on Form S-3 | ||
File No. 333-252471 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the 'Company'), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on February 3, 2021, or as soon thereafter as possible on such date.
Very truly yours, | |
CNS Pharmaceuticals, Inc. | |
By: /s/ Christopher Downs | |
Name: Christopher Downs | |
Title: Chief Financial Officer |